

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for the Offer Shares in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The Offer Shares may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an exemption from the registration requirements of the U.S. Securities Act and U.S. Investment Company Act of 1940, as amended (“**U.S. Investment Company Act**”), and in compliance with any applicable state securities laws. The Offer Shares are being offered and sold outside the United States to investors that are not U.S. persons nor persons acquiring for the account or benefit of U.S. persons in reliance on Regulation S under the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated July 31, 2025 (the “**Prospectus**”) issued by Ab&B Bio-Tech CO., LTD. JS (江蘇中慧元通生物科技股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus.*

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

No stabilizing manager will be appointed, and it is anticipated that no stabilization activities will be carried out in relation to the Global Offering.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Monday, August 11, 2025).



Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering : 33,442,600 H Shares
Number of Hong Kong Offer Shares : 3,996,000 H Shares (as adjusted after reallocation)
Number of International Offer Shares : 29,446,600 H Shares (as adjusted after reallocation)
Offer Price : HK\$12.90 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%
Nominal value : RMB1.00 per H Share
Stock code : 2627

*Joint Sponsors, Overall Coordinators,
Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers*



CITIC SECURITIES



招銀國際
CMB INTERNATIONAL

Joint Bookrunners and Joint Lead Managers



利弗莫尔证券
LIVERMORE HOLDINGS LIMITED



富德證券
FUNDE SECURITIES



雅利多證券
ARISTO SECURITIES LIMITED



中銀國際

BOCI

ICBC



工銀國際

AB&B BIO-TECH CO., LTD. JS/江蘇中慧元通生物科技股份有限公司

ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated July 31, 2025 (the “**Prospectus**”) issued by Ab&B Bio-Tech CO., LTD. JS (江蘇中慧元通生物科技股份有限公司) (the “**Company**”).

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company Information	
Stock Code	2627
Stock short name	AB&B BIO-TECH-B
Dealings commencement date	August 11, 2025*

*see note at the end of the announcement

Price Information	
Final Offer Price	HK\$12.90
Maximum Offer Price	HK\$15.50
Offer Price Adjustment	N/A

Offer Shares and Share Capital	
Number of Offer Shares	33,442,600
Number of Offer Shares in Hong Kong Public Offering (after reallocation)	3,996,000
Number of Offer Shares in International Offering (after the Reallocation)	29,446,600
Number of issued Shares upon Listing	393,442,600

Offer Size Adjustment Option (Upsize option)	
Number of additional shares issued under the option	0
- Public Offer	0
- International Offer	0

Note: The Offer Size Adjustment Option has not been exercised.

Proceeds	
Gross proceeds (Note)	HK\$431.4 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$(48.7) million
Net proceeds	HK\$382.7 million

Note: Gross proceeds refers to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	191,879
No. of successful applications	18,948
Subscription level	4,007.64 times
Claw-back triggered	No
No. of Offer Shares initially available under the Hong Kong Public Offering	3,344,400
No. of Offer Shares reallocated from the International Offering	651,600
Final no. of Offer Shares under the Hong Kong Public Offering (after reallocation)	3,996,000
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	11.95%

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to www.hkeipo.hk/IPOResult to perform a search by identification document number or www.hkeipo.hk/IPOResult for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	152
Subscription Level	0.99 times
No. of Offer Shares initially available under the International Offering	30,098,200
Final no. of Offer Shares under the International Offering (after reallocation)	29,446,600
% of Offer Shares under the International Offering to the Global Offering	88.05%

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investor

<i>Investor</i> ^{Note 1}	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital in the Company after the Global Offering</i>	<i>Existing shareholders or their close associates</i>
Jiaying Xinyang Private Equity Asset Management Co., Ltd. (嘉興鑫揚私募基金管理有限公司) ("Jiaying Xinyang") and Huatai Capital Investment Limited ("HTCI") (in connection with Huatai Back-to-back TRS and Huatai Client TRS)	7,830,600	23.42%	2.64%	1.99%	No
Subtotal	7,830,600	23.42%	2.64%	1.99%	
<i>Note:</i> 1. For further details of the Cornerstone Investor, please refer to the section headed "Cornerstone Investor" in the Prospectus.					

LOCK-UP UNDERTAKINGS

Controlling Shareholders

<i>Name</i> ^{Note 1,2,3,4}	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Jiangsu Tiaoyu Science and Trade Co., Ltd. (江蘇耀宇科貿有限公司) ("Jiangsu Tiaoyu")	112,743,611 (including 78,920,528 H Shares)	26.63%	28.66%	February 10, 2026 (First Six-Month Period) ^{Note 5} August 10, 2026 (Second Six-Month Period) ^{Note 6}
He Yiming (何一鳴) ("Mr. He")	16,267,253 (including 11,387,077 H Shares)	3.84%	4.13%	February 10, 2026 (First Six-Month Period) ^{Note 5}

				August 10, 2026 (Second Six- Month Period) <i>Note 6</i>
Taizhou Huida Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州 慧達企業管理諮詢 服務合夥企業(有限 合夥)) ("Taizhou Huida")	18,707,341 (including 18,642,272 H Shares)	6.29%	4.75%	February 10, 2026 (First Six-Month Period) <i>Note 5</i> August 10, 2026 (Second Six- Month Period) <i>Note 6</i>
Taizhou Huirong Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧融企業管理 諮詢服務合夥企業(有限合夥)) ("Taizhou Huirong")	8,133,626 (including 8,133,626 H Shares)	2.74%	2.07%	February 10, 2026 (First Six-Month Period) <i>Note 5</i> August 10, 2026 (Second Six- Month Period) <i>Note 6</i>
Taizhou Huilong Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧隆企業管理 諮詢服務合夥企業(有限合夥)) ("Taizhou Huilong")	8,133,626 (including 8,133,626 H Shares)	2.74%	2.07%	February 10, 2026 (First Six-Month Period) <i>Note 5</i> August 10, 2026 (Second Six- Month Period) <i>Note 6</i>
Subtotal	163,985,457 (including 125,217,129 H Shares)	42.25%	41.68%	

Notes:

1. Jiangsu Tiaoyu is owned as to 70% by Mr. An Youcai (安有才) ("Mr. An") and 30% by Ms. Cao Hong (曹紅), Mr. An's spouse. Therefore, under the SFO, Mr. An is deemed to be interested in the Shares held by Jiangsu Tiaoyu.
2. Jiangsu Tiaoyu is the general partner of each of Taizhou Huida, Taizhou Huirong, Taizhou Huilong, Taizhou Huixin Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧新企業管理諮詢服務合夥企業(有限合夥)) ("Taizhou Huixin"), Taizhou Huining Enterprise

Management Consulting Service Partnership (Limited Partnership) (泰州慧寧企業管理諮詢服務合夥企業(有限合夥)) ("**Taizhou Huining**") and Taizhou Huijia Enterprise Management Consulting Service Partnership (Limited Partnership) (泰州慧嘉企業管理諮詢服務合夥企業(有限合夥)) ("**Taizhou Huijia**", together with Taizhou Huida, Taizhou Huirong, Taizhou Huilong, Taizhou Huixin, Taizhou Huining, the "**Employee Ownership Platforms**"). Therefore, under the SFO, each of Mr. An and Jiangsu Tiaoyu is deemed to be interested in Shares held by Taizhou Huida, Taizhou Huirong, Taizhou Huilong, Taizhou Huixin, Taizhou Huining and Taizhou Huijia. For details of the Employee Ownership Platforms, please refer to the section headed "History, Development and Corporate Structure—Employee Ownership Platforms" of the Prospectus.

3. Pursuant to the concert party agreement entered into by Mr. An, Jiangsu Tiaoyu and Mr. He in December 2022 (the "**Concert Party Agreement**"), Mr. He confirmed and agreed that he has acted and will continue to act in concert with Mr. An, Jiangsu Tiaoyu and the Directors nominated by each of them at the general meetings and Board meetings (as the case may be) in respect of the management and operations of the Company for a period from January 1, 2020 until 36 months after the signing date of the Concert Party Agreement (being December 12, 2022) or, in the event when the Shares of the Company are publicly offered and listed, 36 months after such offering and listing of the Company on the Stock Exchange. Therefore, under the SFO, each of Mr. An, Jiangsu Tiaoyu and Mr. He is deemed to be interested in the Shares held by each other.
4. Taizhou Huixin is the limited partner of Taizhou Huida, holding approximately 58.26% partnership interests therein. Therefore, under the SFO, Taizhou Huixin is deemed to be interested in Shares held by Taizhou Huida.
5. In accordance with the relevant Listing Rules/guidance materials, the required lock-up for the first six-month period ends on February 10, 2026. The Controlling Shareholder may dispose of or transfer Shares after the indicated date provided that the Controlling Shareholder will not cease to be a Controlling Shareholder, subject to compliance with applicable requirements under the PRC Company Law.
6. In accordance with the relevant Listing Rules/guidance materials, the required lock-up for the second six-month period ends on August 10, 2026. The Controlling Shareholder will cease to be prohibited from disposing of or transferring Shares after the indicated date, subject to compliance with applicable requirements under the PRC Company Law.

Pre-IPO Investors

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing	% of Shares subject to lock-up undertakings as to total issued Shares upon Listing	Last day subject to the lock-up undertakings
Jiangsu Jiequan Gaotejia Medical Industry Investment Fund (Limited Partnership) (江蘇隼泉高特佳醫療產業投資基金(有	29,708,884 (including 14,854,442 H Shares)	5.01%	7.55%	August 10, 2026 Note 2

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
限合夥))				
Zhuzhou National Innovation Medicine Investment Partnership (Limited Partnership) (株洲市國創新藥投資合夥企業(有限合夥)) ("Zhuzhou National Innovation") ^{Note 3}	9,645,017 (including 2,893,505 H Shares)	0.98%	2.45%	August 10, 2026 ^{Note 2}
Pingtang Wenzhou Hangshi Ruihui Investment Partnership (Limited Partnership) (平潭文周杭實瑞慧投資合夥企業(有限合夥)) ("Pingtan Wenzhou Hangshi") ^{Note 3}	8,593,339 (including 6,445,004 H Shares)	2.17%	2.18%	August 10, 2026 ^{Note 2}
Pingtang Wenzhou Ruixi Investment Partnership (Limited Partnership) (平潭文周瑞璽投資合夥企業(有限合夥)) ("Pingtan Wenzhou Ruixi") ^{Note 3}	1,719,449 (including 1,289,587 H Shares)	0.44%	0.44%	August 10, 2026 ^{Note 2}
Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership) (株洲市文周君喆創業投資合夥企業(有限合夥)) ("Zhuzhou Wenzhou Junzhe") ^{Note 3}	1,712,942 (including 1,284,706 H Shares)	0.43%	0.44%	August 10, 2026 ^{Note 2}
Qingdao Yingke Value Venture Capital Partnership (Limited Partnership) (青島盈科價值創業投資合夥企業(有限合夥)) ("Qingdao Yingke Value") ^{Note 3}	12,890,009 (including 6,445,004 H Shares)	2.17%	3.28%	August 10, 2026 ^{Note 2}

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
合夥)) ("Qingdao Yingke Value Venture") ^{Note 4}				
Qingdao Yingke Dingxin No. 1 Venture Capital Partnership (Limited Partnership) (青島盈科鼎新一號創業投資合夥企業(有限合夥)) ("Qingdao Yingke Dingxin No. 1") ^{Note 4}	1,744,500 (including 872,250 H Shares)	0.29%	0.44%	August 10, 2026 ^{Note 2}
Pingtian Puxin Yingke Ruiyuan Venture Capital Partnership (Limited Partnership) (平潭浦信盈科睿遠創業投資合夥企業(有限合夥)) ("Pingtan Puxin Yingke") ^{Note 4}	1,718,635 (including 1,718,635 H Shares)	0.58%	0.44%	August 10, 2026 ^{Note 2}
Zibo Yingke Growth No. 2 Venture Capital Partnership (Limited Partnership) (淄博盈科成長二號創業投資合夥企業(有限合夥)) ("Zibo Yingke Growth No. 2") ^{Note 4}	833,534 (including 416,767 H Shares)	0.14%	0.21%	August 10, 2026 ^{Note 2}
Zhuzhou Sealand Guochuang Qianjin Pharmaceutical Venture Capital Partnership (Limited Partnership) (株洲市國海國創千金醫藥創業投資合夥企業(有限合夥)) ("Zhuzhou Sealand Guochuang") ^{Note 5}	6,015,305 (including 0 H Shares)	0.00%	1.53%	August 10, 2026 ^{Note 2}
Shenzhen Sealand No. 5 Innovative Pharmaceutical	4,232,251 (including 0 H Shares)	0.00%	1.08%	August 10, 2026 ^{Note 2}

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Investment Partnership (Limited Partnership) (深圳市國海伍號創新醫藥投資合夥企業(有限合夥)) ("Shenzhen Sealand No.5") <small>Note 5</small>				
Guangxi Sealand Yuchai Venture Capital Partnership (Limited Partnership) (廣西國海玉柴金投創業投資合夥企業(有限合夥)) ("Sealand Yuchai") <small>Note 5</small>	3,591,159 (including 3,591,159 H Shares)	1.21%	0.91%	August 10, 2026 <small>Note 2</small>
Xi'an Sealand Jingheng Venture Capital Co., Ltd. (西安國海景恒創業投資有限公司) ("Sealand Jingheng") <small>Note 5</small>	2,052,114 (including 2,052,114 H Shares)	0.69%	0.52%	August 10, 2026 <small>Note 2</small>
HLC Healthmedical HK Limited	12,030,772 (including 12,030,772 H Shares)	4.06%	3.06%	August 10, 2026 <small>Note 2</small>
Taizhou Jintai Hongyi Entrepreneurship Investment Fund (Limited Partnership) (泰州市金泰弘毅創業投資基金(有限合夥))	9,903,016 (including 9,903,016 H Shares)	3.34%	2.52%	August 10, 2026 <small>Note 2</small>
Hangzhou Sanhua Hongdao Venture Capital Partnership Enterprise (Limited Partnership) (杭州三花弘道創業投資合夥企業(有限合夥)) ("Hangzhou Sanhua Hongdao") <small>Note 6</small>	6,586,611 (including 6,586,611 H Shares)	2.22%	1.67%	August 10, 2026 <small>Note 2</small>

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Xinchang Yujun Shanghang Venture Capital Partnership (Limited Partnership) (新昌鈺俊尚行創業投資合夥企業(有限合夥)) ("Yujun Shanghang") ^{Note 6}	2,148,091 (including 2,148,091 H Shares)	0.72%	0.55%	August 10, 2026 ^{Note 2}
Jiangsu Province Modern Service Industry Development Venture Capital Fund (Limited Partnership) (江蘇省現代服務業發展創業投資基金(有限合夥)) ("Jiangsu Modern Service Fund") ^{Note 7}	3,078,252 (including 3,078,252 H Shares)	1.04%	0.78%	August 10, 2026 ^{Note 2}
Taizhou Transition and Upgrading Industrial Investment Fund (Limited Partnership) (泰州市轉型升級產業投資基金(有限合夥)) ("Taizhou Transition and Upgrading Fund") ^{Note 7}	3,078,252 (including 3,078,252 H Shares)	1.04%	0.78%	August 10, 2026 ^{Note 2}
Taizhou China Pharmaceutical City Class I New Drug R&D Investment Fund Partnership Enterprise (Limited Partnership) (泰州中國醫藥城一類新藥研發投資基金合夥企業(有限合夥))	6,156,342 (including 3,078,171 H Shares)	1.04%	1.56%	August 10, 2026 ^{Note 2}
Anji Aiweidi Enterprise Management Partnership (Limited Partnership) (安吉愛威笛企業管	4,066,813 (including 0 H Shares)	0%	1.03%	August 10, 2026 ^{Note 2}

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
理合夥企業(有限合夥)) ("Anji Aiweidi") Note 8				
Shangshan Ruoshui (Beijing) Fund Management Co., Ltd. (上善若水(北京)基金管理有限公司) ("Shangshan Ruoshui") Note 8	2,052,114 (including 2,052,114 H Shares)	0.69%	0.52%	August 10, 2026 Note 2
Shenzhen Songhe Jiyou No. 3 Venture Capital Partnership (Limited Partnership) (深圳市松禾績優三號創業投資合夥企業(有限合夥))	4,296,670 (including 2,148,335 H Shares)	0.72%	1.09%	August 10, 2026 Note 2
Shenzhen Co-win Yuanshui Investment Partnership (Limited Partnership) (深圳共贏源水投資合夥企業(有限合夥))	4,137,413 (including 4,137,413 H Shares)	1.40%	1.05%	August 10, 2026 Note 2
Yangzhou Yingdan Equity Investment Partnership (Limited Partnership) (揚州盈丹股權投資合夥企業(有限合夥)) Note 9	4,115,615 (including 2,057,807 H Shares)	0.69%	1.05%	August 10, 2026 Note 2
Gongqingcheng Chengshu Phase V Medical Industry Investment Partnership (Limited Partnership) (共青城承樹五期醫療產業投資合夥企業(有限合夥))	3,437,271 (including 3,437,271 H Shares)	1.16%	0.87%	August 10, 2026 Note 2
Hangzhou Fushi Investment Management Partnership (Limited Partnership)	3,345,361 (including 1,672,681 H Shares)	0.56%	0.85%	August 10, 2026 Note 2

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
(杭州賦實投資管理合夥企業(有限合夥))				
Shenzhen Gaotejia Ruibao Investment Partnership (Limited Partnership) (深圳市高特佳睿寶投資合夥企業(有限合夥))	3,300,951 (including 3,300,951 H Shares)	1.11%	0.84%	August 10, 2026 Note 2
Nanjing Yihui Entrepreneurship Investment Partnership Enterprise (Limited Partnership) (南京益慧創業投資合夥企業(有限合夥)) ("Yihui Chuangtou") Note 10	2,377,459 (including 2,377,459 H Shares)	0.80%	0.60%	August 10, 2026 Note 2
Nanjing Yidao Equity Investment Partnership (Limited Partnership) (南京益道股權投資合夥企業(有限合夥)) ("Nanjing Yidao") Note 10	859,399 (including 859,399 H Shares)	0.29%	0.22%	August 10, 2026 Note 2
Shenzhen Dongqi Investment Development Enterprise (Limited Partnership) (深圳東淇投資發展企業(有限合夥))	3,028,149 (including 3,028,149 H Shares)	1.02%	0.77%	August 10, 2026 Note 2
Yangzhou Litian New Drug Investment Partnership Enterprise (Limited Partnership) (揚州利田新藥投資合夥企業(有限合夥)) Note 11	2,352,895 (including 2,352,895 H Shares)	0.79%	0.60%	August 10, 2026 Note 2
Guangxi Guangtou Guohong Health Industry Fund Partnership Enterprise	1,718,635 (including 0 H Shares)	0%	0.44%	August 10, 2026 Note 2

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
(Limited Partnership) (廣西廣投國宏健康產業基金合夥企業(有限合夥))				
Yangzhou Xuantan Investment Co., Ltd. (揚州玄壇投資有限公司) ^{Note 12}	1,626,725 (including 650,705 H Shares)	0.22%	0.41%	August 10, 2026 ^{Note 2}
Qingdao Qiandao Yingyue Investment Management Center (Limited Partnership) (青島乾道盈悅投資管理中心(有限合夥))	859,399 (including 859,399 H Shares)	0.29%	0.22%	August 10, 2026 ^{Note 2}
Shenzhen Zhiyou Pengbo Management Consulting Partnership (Limited Partnership) (深圳市志友蓬勃管理諮詢合夥企業(有限合夥))	257,836 (including 257,836 H Shares)	0.09%	0.07%	August 10, 2026 ^{Note 2}
Subtotal	169,271,179 (including 110,958,752 H Shares)	37.44%	43.02%	

Notes:

1. Please refer to the section headed “History, Development and Corporate Structure — Pre-IPO Investments — Information about Our Pre-IPO Investors” in the Prospectus for details of the Pre-IPO Investors.
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
3. Each an investment arm of Shanghai Wenzhou Investment Management Co., Ltd. (上海文周投資管理有限公司).
4. Each an investment arm of Yingke Innovation Asset Management Co., Ltd. (盈科創新資產管理有限公司).
5. Each an investment arm of Sealand Innovation Capital Investment Management Co., Ltd. (國海創新資本投資管理有限公司).
6. Each ultimately controlled by Mr. Chen Jinyu (陳金玉).

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing	% of Shares subject to lock-up undertakings as to total issued Shares upon Listing	Last day subject to the lock-up undertakings
7.	Each an investment arm of Taizhou Yida is Nanjing Yida Equity Investment Management Enterprise (Limited Partnership) (南京毅達股權投資管理企業(有限合夥)).			
8.	Anji Aiweidi is ultimately controlled by Mr. Lu Yingxu (盧迎旭); and Shangshan Ruoshui is controlled as to 60% by Mr. Lu Yubo (盧玉波), father of Mr. Lu Yingxu, and 40% by Mr. Lu Yingxu.			
9.	Yangzhou Yingdan Equity Investment Partnership (Limited Partnership) (揚州盈丹股權投資合夥企業(有限合夥)) is formerly known as Guangdong Yingdan Equity Investment Partnership (Limited Partnership) (廣東盈丹股權投資合夥企業(有限合夥)).			
10.	Each an investment arm of Nanjing Changchengit Equity Investment Fund Management Enterprise (Limited Partnership) (南京常呈益股權投資基金管理企業(有限合夥)).			
11.	Yangzhou Litian New Drug Investment Partnership Enterprise (Limited Partnership) (揚州利田新藥投資合夥企業(有限合夥)) is formerly known as Zhuzhou Litian New Drug Enterprise Management Partnership (Limited Partnership) (株洲市利田新藥企業管理合夥企業(有限合夥)).			
12.	Yangzhou Xuantan Investment Co., Ltd. (揚州玄壇投資有限公司) is formerly known as Guangdong Xuantan Investment Co., Ltd. (廣東玄壇投資有限公司).			

Existing Shareholders (other than the Controlling Shareholders and the Pre-IPO Investors as defined in the Prospectus)

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing	% of Shares subject to lock-up undertakings as to total issued Shares upon Listing	Last day subject to the lock-up undertakings
Shanghai Yijiucheng Investment Co., Ltd. (上海憶久誠投資有限公司)	26,743,364 (including 26,743,364 H Shares)	9.02%	6.80%	August 10, 2026 <i>Note 1</i>
Subtotal	26,743,364 (including 26,743,364 H Shares)	9.02%	6.80%	
<i>Note:</i>				
1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.				

Cornerstone Investor

<i>Name</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of H Shares subject to lock-up undertakings as to total issued H Shares upon Listing</i>	<i>% of Shares subject to lock-up undertakings as to total issued Shares upon Listing</i>	<i>Last day subject to the lock-up undertakings^{Note 1}</i>
Jiaying Xinyang and HTCI (in connection with Huatai Back-to-back TRS and Huatai Client TRS)	7,830,600	2.64%	1.99%	February 10, 2026
<p><i>Notes:</i></p> <p>1. <i>In accordance with the relevant cornerstone investment agreement, the required lock-up ends on February 10, 2026. The Cornerstone Investor will cease to be prohibited from disposing of or transferring H Shares subscribed pursuant to the relevant cornerstone investment agreement after the indicated date.</i></p>				

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of H Shares held as to total issued H Shares upon Listing	% of H Shares held as to total issued Shares upon Listing
Top 1	9,800,000	33.28%	29.30%	9,800,000	3.31%	2.49%
Top 5	27,810,000	94.44%	83.16%	27,810,000	9.38%	7.07%
Top 10	29,394,600	99.82%	87.90%	29,394,600	9.92%	7.47%
Top 25	29,419,400	99.91%	87.97%	29,419,400	9.93%	7.48%

Note:

* *Ranking of placees is based on the number of H Shares allotted to the placees.*

H SHAREHOLDER CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of H Shares held as to total issued H Shares upon Listing	% of H Shares held as to total issued Shares upon Listing	% of Shares held as to total issued Shares upon Listing
Top 1	-	0.00%	0.00%	125,217,129	42.25%	31.83%	41.68%
Top 5	-	0.00%	0.00%	190,758,509	64.37%	48.48%	64.59%
Top 10	17,630,600	59.87%	52.72%	236,479,483	79.79%	60.11%	78.18%
Top 25	27,810,000	94.44%	83.16%	287,288,624	96.94%	73.02%	96.58%

Note:

* *Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of H Shares held as to total issued H Shares upon Listing	% of Shares held as to total issued Shares upon Listing
Top 1	-	0.00%	0.00%	125,217,129	163,985,457	42.25%	41.68%
Top 5	-	0.00%	0.00%	188,180,393	259,295,130	63.50%	65.90%
Top 10	9,800,000	33.28%	29.30%	234,292,156	315,654,449	79.06%	80.23%
Top 25	25,984,800	88.24%	77.70%	287,136,105	381,522,205	96.89%	96.97%

Note:

* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon Listing.*

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 191,879 valid applications made by the public will be conditionally allocated on the basis set out below:

		Pool A	Approximate percentage allotted of the total number of H Shares applied for
Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot	
200	33,581	336 out of 33,581 applicants to receive 200 H Shares	1.00%
400	6,889	94 out of 6,889 applicants to receive 200 H Shares	0.68%
600	15,279	247 out of 15,279 applicants to receive 200 H Shares	0.54%
800	4,125	76 out of 4,125 applicants to receive 200 H Shares	0.46%
1,000	6,226	126 out of 6,226 applicants to receive 200 H Shares	0.40%
1,200	4,499	99 out of 4,499 applicants to receive 200 H Shares	0.37%
1,400	3,519	83 out of 3,519 applicants to receive 200 H Shares	0.34%
1,600	2,292	57 out of 2,292 applicants to receive 200 H Shares	0.31%
1,800	1,958	52 out of 1,958 applicants to receive 200 H Shares	0.30%
2,000	10,789	295 out of 10,789 applicants to receive 200 H Shares	0.27%
3,000	7,573	248 out of 7,573 applicants to receive 200 H Shares	0.22%
4,000	4,009	149 out of 4,009 applicants to receive 200 H Shares	0.19%
5,000	3,323	136 out of 3,323 applicants to receive 200 H Shares	0.16%
6,000	5,770	255 out of 5,770 applicants to receive 200 H Shares	0.15%
7,000	2,970	141 out of 2,970 applicants to receive 200 H Shares	0.14%
8,000	2,167	109 out of 2,167 applicants to receive 200 H Shares	0.13%
9,000	1,775	94 out of 1,775 applicants to receive 200 H Shares	0.12%
10,000	13,487	745 out of 13,487 applicants to receive 200 H Shares	0.11%
20,000	9,337	698 out of 9,337 applicants to receive 200 H Shares	0.07%
30,000	5,624	502 out of 5,624 applicants to receive 200 H Shares	0.06%
40,000	4,600	465 out of 4,600 applicants to receive 200 H Shares	0.05%
50,000	3,276	366 out of 3,276 applicants to receive 200 H Shares	0.04%
60,000	2,856	345 out of 2,856 applicants to receive 200 H Shares	0.04%
70,000	2,523	326 out of 2,523 applicants to receive 200 H Shares	0.04%
80,000	1,781	244 out of 1,781 applicants to receive 200 H Shares	0.03%
90,000	1,507	218 out of 1,507 applicants to receive 200 H Shares	0.03%
100,000	8,561	1,292 out of 8,561 applicants to receive 200 H Shares	0.03%
200,000	5,385	1,100 out of 5,385 applicants to receive 200 H Shares	0.02%
300,000	4,480	1,092 out of 4,480 applicants to receive 200 H Shares	0.02%
Total	180,161	Total number of Pool A successful applicants: 9,990	

		Pool B	Approximate percentage allotted of the total number of H Shares applied for
Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot	
400,000	4,853	2,912 out of 4,853 applicants to receive 200 H Shares	0.03%
500,000	1,513	1,051 out of 1,513 applicants to receive 200 H Shares	0.03%
600,000	1,030	806 out of 1,030 applicants to receive 200 H Shares	0.03%

700,000	799	692 out of 799 applicants to receive 200 H Shares	0.02%
800,000	476	450 out of 476 applicants to receive 200 H Shares	0.02%
900,000	338	200 H Shares plus 7 out of 338 applicants to receive an additional 200 H Shares	0.02%
1,000,000	567	200 H Shares plus 53 out of 567 applicants to receive an additional 200 H Shares	0.02%
1,200,000	365	200 H Shares plus 85 out of 365 applicants to receive an additional 200 H Shares	0.02%
1,400,000	316	200 H Shares plus 115 out of 316 applicants to receive an additional 200 H Shares	0.02%
1,672,200	1,461	200 H Shares plus 772 out of 1,461 applicants to receive an additional 200 H Shares	0.02%
Total	11,718	Total number of Pool B successful applicants: 8,958	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHERS / ADDITIONAL INFORMATION

Offer Size Adjustment Option and reallocation

The Offer Size Adjustment Option has not been exercised. As the International Offering has not been fully subscribed and the Hong Kong Public Offering has been oversubscribed, the reallocation as described in the section headed "Structure of the Global Offering – The Hong Kong Public Offering – Reallocation and clawback" of the Prospectus has been applied. As a result of the above, the final number of Offer Shares under the Hong Kong Public Offering is adjusted to 3,996,000 Shares, representing approximately 11.95% of the total number of Offer Shares available under the Global Offering, and the final number of Offer Shares under the International Offering is adjusted to 29,446,600 Shares, representing approximately 88.05% of the total number of Offer Shares under the Global Offering.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for the Offer Shares in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the "U.S. Securities Act") or securities law of any state or other jurisdiction of the United States. The Offer Shares may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an exemption from the registration requirements of the U.S. Securities Act and U.S. Investment Company Act of 1940, as amended ("U.S. Investment Company Act"), and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States.

The Offer Shares are being offered and sold outside the United States to investors that are not U.S. persons nor persons acquiring for the account or benefit of U.S. persons in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated July 31, 2025 issued by Ab&B Bio-Tech CO., LTD. JS (江蘇中慧元通生物科技股份有限公司) for detailed information about the Global Offering described

below before deciding whether or not to invest in the H Shares thereby being offered.

**Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on August 11, 2025).*

PUBLIC FLOAT

Immediately following the completion of the Global Offering, an aggregate of 132,488,550 H Shares or approximately 33.67% of the total issued share capital of the Company will be held in the public hands. Therefore, the number of H Shares in the public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the H shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, August 11, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Monday, August 11, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Monday, August 11, 2025 (Hong Kong time). The H Shares will be traded in board lots of 200 H Shares each, and the stock code of the H Shares will be 2627.

By order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai

Executive Director, chairman of the Board and general manager

Hong Kong, August 8, 2025

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Ms. LI Xiaoqing and Mr. CHEN Chengbei as independent non-executive Directors.